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Hiilihappoanhydraasi III (CA III) on sytosolissa sijaitseva entsyymi, jota esiintyy runsaasti poikkijuovaisissa 
lihassoluissa. Hiljattain CA III:n on todettu ottavan osaa moniin fysiologisiin tapahtumasarjoihin. 
Tässä katsauksessa tarkastellaan CA III:n rakennetta, toimintaa ja ilmentymistä eri kudoksissa sekä erilaisten 
kemiallisten yhdisteiden vaikutusta CA III:n entsymaattiseen aktiivisuuteen. Lisäksi artikkelissa esitellään uutta 
tietoa CA III:n ilmentymisestä hiiren kudoksissa. 
Artikkelissa on käsitelty olennaisimpia CA III:sta julkaistuja tutkimuksia. Uutta tietoa entsyymin jakaumasta 
hiiren kudoksissa on saatu immunohistokemiallisen värjäyksen sekä western blotting –menetelmän avulla.  
CA III:n ilmentymä on suurinta poikkijuovaisissa lihassoluissa sekä maksassa. Useat muut kudokset sisältävät 
pienempiä määriä tätä entsyymiä. Tauteja, joihin liittyy CA III:n viallinen ekspressio tai toiminta, voidaan 
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Context: Carbonic anhydrase III (CA III) is a cytosolic enzyme which is known to be highly expressed in the 
skeletal muscle and has been recently linked to important roles in several physiological processes. 
Objective: This review is focused on properties of CA III, including its distribution, function, structure and 
modulation of enzymatic activity by activators or inhibitors. We also provide some novel data on its expression 
in murine tissues.  
Methods:  In this article, the most relevant literature on CA III has been covered. New information on the 
distribution has been obtained by immunohistochemical staining and western blotting.  
Results and conclusion: CA III shows the highest expression in the skeletal muscle and liver. Several other 
tissues contain lower levels of the enzyme. Activation or inhibition of CA III may offer a novel opportunity to 





Carbonic anhydrases (CAs) are zinc-containing metalloenzymes that are highly expressed in vertebrates 
including humans (Supuran 2008). CAs are encoded by four distinct gene families (Supuran ja Scozzafava 2007).  
The ɲ-CA gene family is dominant in vertebrates, while the other families are mainly present in bacteria, algae 
and green plants. The CA isozymes differ in their kinetic properties, tissue distributions and subcellular 
localizations (Lehtonen ym. 2004). The mammalian ɲ-CA gene family is characterized by 16 different isoforms, 
13 of which (CA I, II, III, IV, VA, VB, VI, VII, IX, XII, XIII, XIV, and XV) are enzymatically active, while the other 
three, the CA-related proteins (CARPs) VIII, X, and XI, lack CA activity (Aspatwar ym. 2010, Supuran ja 
Scozzafava 2007, Taniuchi ym. 2002). CA XV is not expressed in primates, and therefore there are only 15 
isoforms expressed in humans (Neri ja Supuran 2011). Five of the active CA isozymes are cytosolic (CA I, II, III, 
VII, and XIII) (Lehtonen ym. 2004, Sly ja Hu 1995) and five are membrane-associated enzymes (CA IV, IX, XII, XIV, 
and XV) (Parkkila ym. 2001, Pastorekova ym. 1997). CAs VA and VB are found in mitochondria (Fujikawa-Adachi 
ym. 1999), and CA VI is a secretory protein present in saliva and milk (Karhumaa ym. 2001, Kivela ym. 1999). 
Most CAs are efficient catalysts for a simple physiological reaction, the hydration of carbon dioxide to 
bicarbonate and protons: COЇ + HЇO <-> HЇCOЈ <-> HЀ + HCOЈЁ (Breton 2001, Hilvo ym. 2004). The CAs catalyze 
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only the first reaction, while the second occurs instantly. The CAs are produced in different tissues where they 
participate in numerous biological processes, such as acid-base balance, respiration, carbon dioxide and ion 
transport, bone resorption, ureagenesis, gluconeogenesis, body fluid generation, and lipogenesis (Lehtonen 
ym. 2004, Sly ja Hu 1995). In addition to these variable physiological processes, the CAs also participate in 
many pathological processes (Supuran ja Scozzafava 2007). Recently, several studies have identified different 
CA isozymes in tumors where they contribute to acidification of the extracellular space, which has been linked 
to the malignant behaviour of cancer cells. At least three CA isozymes, CA II, CA IX and CA XII, are 
overexpressed in various tumors, and are therefore associated with cancer progression (Neri ja Supuran 2011, 
Parkkila 2008). Many of the CA enzymes are intriguing as drug targets, and some CA inhibitors are already 
clinically used as therapeutic agents in the prevention and treatment of many diseases including glaucoma and 
epilepsy (Mincione ym. 2008, Thiry ym. 2007). Currently, novel anticancer therapies targeted to CA IX and CA 
XII are widely investigated (Battke ym. 2011, Parkkila 2008). 
 
In the current review, we explore the data that have emerged on carbonic anhydrase III (CA III). Here, we 
present the basic structure and putative function of this enzyme. In addition, we explore the activators and 
inhibitors of CA III. Furthermore, this review contains information of the distribution pattern of CA III in 
different rodent and human tissues. We also present novel data on the localization of CA III in various mouse 
tissues. To our knowledge this was the first time when the localization of CA III was thoroughly investigated in 





The distribution of CA III has been previously studied mainly in human and rat tissues. In rats, CA III is 
remarkably abundant in the Type I (slow twitch) skeletal muscle (Jeffery ym. 1986, Wade ym. 1986), adipocytes 
(Spicer ym. 1990a, Stanton ym. 1991) and liver, where it has been localized to the perivenous zone (Carter ym. 
2001, Kelly ym. 1991). Lower concentrations of the enzyme have been detected in the Type II (fast twitch) 
skeletal muscle, heart, prostate, kidney, brain, and erythrocytes (Shiels ym. 1984). CA III has also been located 
in the epithelium in some regions of the salivary gland ducts, colon, bronchi and male genital tract (Spicer ym. 
1990b). In humans, CA III has been found abundantly in the skeletal muscle (Kato ja Mokuno 1984). It appears 
that the concentration of CA III in the Type I fibers is higher than in the Type II fibers, a phenomenon also 
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detected in rats (Shima 1984, Vaananen ym. 1985, Zheng ym. 1992). Trace levels of CA III have also been 
detected in the human smooth muscle, heart and lung (Jeffery ym. 1980). 
 
The concentration of CA III has been found to be higher in the liver of male rats than in female rats (Shiels ym. 
1984). Androgen-linked control of CA III expression was investigated by Carter et al. (Carter ym. 2001) using a 
radioimmunosorbent technique. They found that castration of males reduced the CA III concentration to the 
same level as in females, while testosterone treatment partially restored the enzyme levels. They assumed that 
CA III belongs to the enzymes of rat liver, which are regulated via the hypothalamo-pituitary-liver axis. 
Immunohistochemistry also showed that the regulation of CA III is confined to the perivenous hepatocytes.  
 
 
Figure 1. Western blot of recombinant human CA III identified with the new anti-CA III antibody. The antibody 
identifies a single 30-kDa polypeptide band. No reactions are seen with the other isozymes. 
 
 
Figure 2. Western blotting of mouse tissues. The strongest 30-kDa polypeptide bands of CA III are detected in 
the liver, soleus and EDL muscles. Moderate or very faint bands are seen in the stomach, ileum, colon, 
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submandibular gland, kidney, testis, epididymis, uterus, heart, lung, and cerebellum. Female (above) and male 
(below) mouse tissues were investigated separately. 
 
Nevertheless, the marked sex-related difference in CA III distribution, described for rat liver, was not seen in 
the mouse (Tweedie ja Edwards 1989).  
 
Our laboratories have recently produced recombinant human CA III protein in Escherichia coli (Bootorabi ym. 
2011), and the enzyme was used to raise specific anti-human CA III serum in a rabbit. The novel anti-CA III 
antibody, which strongly identified a single 30-kDa polypeptide band on the western blot of the purified 
recombinant human CA III while recognized no other CA isozyme (Figure 1), was further used to study the 
distribution pattern of CA III in mouse tissues by western blotting (Figure 2) and immunohistochemistry 
(Figures 3-5). The results obtained in this study are summarized in Table 1, which provides a basic overview of 
CA III distribution in mouse tissues. Our findings indicated the highest expression in the striated muscle and 
liver. Also, the pancreatic ɲ-cells showed strong immunohistochemical staining, but there was no detectable 
signal from total pancreas extracts in western blotting. On the basis of western blot results, the stomach, 
kidney, submandibular gland, heart, cerebellum, and testis expressed CA III. Immunohistochemical staining 
confirmed that the gastric surface epithelial cells, renal tubules, epithelium of the submandibular salivary 
ducts, heart, some neuronal axons of the cerebellum, and testicular interstitial cells were indeed positive for 
CA III immunostaining. Other tissues, including the ileum, colon and lung, also showed weak signals for CA III in 
the western blot, suggesting that the expression rate is relatively low in those tissues. The results of this study 
are mainly in agreement with the previously published data from other species. The rat liver, striated muscle 
(Kelly ym. 1991, Shiels ym. 1984, Spicer ym. 1990a) and human skeletal muscle (Jeffery ym. 1980, Vaananen 
ym. 1985, Wade ym. 1986, Zheng ym. 1992) are commonly known to contain large amounts of CA III. Previous 
investigations have provided variable information about the expression of CA III in tissues where the enzyme’s 
concentration is low and therefore hard to detect. We can assume, though, that the main physiological 
functions of the enzyme occur in cells where its concentration is high.  
 
In the present study, we showed that CA III is abundantly expressed in the ɲ-cells of the pancreatic Langerhans 
islets. This finding raises an interesting question about the function of CA III in the pancreas. Previous studies 
indicate that CA I is also expressed in the pancreatic ɲ-cells, though there is no information about its functions 
in this endocrine cell population (Parkkila ym. 1995). Therefore, an interesting area for future investigations 





Figure 3. Immunohistochemical staining of CA III in different mouse tissues. The EDL muscle (a) shows 
occasional strongly stained muscle fibers, while a weaker positive signal is observed in the heart (b). The kidney 
(c) shows only very faint staining in the renal tubules. In the testis (d), a very weak positive signal is detected in 
the interstitial cells (arrow). The lung (e) and spleen (f) are completely negative. Bars 50 µm. 
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In our study, immunohistochemical staining provided evidence that CA III is present in the internal capsule and 
some neurons of the hypothalamus as well as some neuronal axons and Purkinje cells of the cerebellum. In 
western blot, a weak signal was also observed for CA III in the cerebellum, while the cerebrum remained 
negative. The presence of CA IX and XIV in the human and mouse brain has been previously established (Hilvo 
ym. 2004, Parkkila ym. 2001). The membrane-bound CA activity has been suggested to participate in the 
production of an alkaline shift linked to neuronal signal transduction (Parkkila ym. 2001). Another cytosolic CA 
isoform, CA VII, has also been demonstrated to participate in the central nervous system physiology 
(Ruusuvuori ym. 2004). CA VII acts as a key molecule in the generation of high frequency stimulation –induced 
tonic GABAergic excitation and it may also have a crucial role in shaping integrative functions and long-term 
plasticity. The results of the present study suggest that CA III might be another isozyme that is expressed in 
some neurons, even though its expression and enzyme activity levels are low. In earlier studies, it had also 
been designated that CA III, as well as other CA isoforms, are present in the epithelial cells of rodent and 
human choroid plexuses, where they participate in the production of the cerebrospinal fluid and regulation of 
its ionic content (Halmi ym. 2006, Nogradi ym. 1993). Yet the presence of CA III in the mouse choroid plexus 
was not detected in this study. 
 
Many studies have confirmed that the CA III concentrations are remarkably high in both the rodent and human 
Type I fibers of skeletal muscle. To date, a lot of research has been made to elucidate the value of CA III as a 
diagnostic marker for rhabdomyolysis and neuromuscular diseases (Syrjala ym. 1990). Evidently, serum CA III 
concentration is elevated in healthy subjects following exercise as well as in patients with neuromuscular 
disease (Vaananen ym. 1988). The enzyme is released into circulation after muscle injury. It has been suggested 
that the serum myoglobin/CA III ratio could be a potential, early diagnostic indicator for myocardial infarction 
(Beuerle ym. 2000, Vaananen ym. 1990). The ratio tends to rise since CA III is not expressed in the myocardium 
to the same extent as myoglobin. Vuotikka et al. (Vuotikka ym. 2003) also demonstrated that measuring the 
myoglobin/CA III ratio during the first hours after initiation of thrombolytic therapy could be useful in 




Figure 4. Immunohistochemical staining of CA III in mouse gastrointestinal organs. In the liver (a), the most 
intense staining is observed in the hepatocytes of perivenular region (cv, central vein). Control staining using 
pre-immune rabbit serum is negative except for nonspecific nuclear reactions (b). In the submandibular gland 
(c), the epithelial cells of the salivary duct (arrows) show very weak immunostaining. The stomach also shows a 







CA III is a cytosolic protein with molecular weight of near 30 kDa (Tu ym. 1994). It was first characterized from 
human skeletal muscle in 1979 (Carter ym. 1979). Its overall structure is quite similar to CA II, and there is a 
62% identity in the amino acid sequences of these two isozymes in humans (Tu ym. 1994). However, CA III has 
a COЇ hydration activity of about 0.3% compared to CA II (Supuran ja Scozzafava 2007). The underlying cause 
for this is the major differences in the active site region of the enzyme: the presence of Lys64 and Phe198 in CA 
III. CA II contains a His residue in position 64, which is much more effective as a proton shuttle than Lys residue 
(An ym. 2002, Elder ym. 2007). In order to regenerate the basic form of the enzyme from the catalytically 
inactive form, a proton transfer reaction takes place (Supuran ja Scozzafava 2007). This reaction is assisted by 
the proton shuttles, and it is considered a rate-limiting step in the catalysis of COЇ hydration. Furthermore, 
position 198 in CA II is occupied by a Leu residue. Leu198 forms part of the hydrophobic pocket of the active 
site cavity of CA II, which is essential for binding COЇ in the neighborhood of nucleophilic zinc-bound water. 
Kinetic and structural evidence indicates that the phenyl side chain of Phe198 in human CA III is a steric 
constriction in the active site and may cause altered interactions at the zinc-bound solvent, resulting in 
decreased catalytic activity of CA III (Duda ym. 2005). In previous studies, Phe198 in CA III has been replaced 
with several other amino acids using site-directed mutagenesis. The results concluded that the replacement of 
Phe198 by other amino acids markedly increases the CA III activity (Tu ym. 1994). The largest effects were 
observed with the replacement of Phe to Asp (LoGrasso ym. 1993). 
 
In addition to its classical COЇ hydration activity, CA III also shows significant phosphatase activity (Koester ym. 
1981). Even though a previous study suggested that the phosphatase activity is related to another protein 
present in the purified enzyme fraction (Kim ym. 2000), it was recently shown that recombinant CA III exhibits 
significant phosphatase activity and is more efficient as a phosphatase than CA II (Truppo ym. 2012). 
 
Physiological role of CA III has turned out to be complicated, and interestingly, despite many studies the 
primary function of CA III is yet to be determined. To elucidate its function Kim et al. (Kim ym. 2004) created a 
mouse lacking a functional Car3 by gene deletion. The analysis of a knockout mouse strain (Car3оͬо) revealed 
that mice lacking CA III develop normally, are fertile and have a normal life span. The major properties of 
muscle cells also appeared unchanged, despite minor disturbances which may have occurred. It was 
hypothesized that CA III is required for an effective response to specific stresses which mice do not encounter 




Figure 5. Immunostaining of CA III in the mouse brain. In the cerebrum, the capsula interna (a) shows moderate 
positive reaction, while the control staining is negative (b). (ci, capsula interna; s, striatum). Some neurons in 
the hypothalamic region are stained (c) (h, hypothalamus). Control shows no reaction (d). (e) A higher-
magnification image in which the CA III-positive staining in the hypothalamic neurons (arrows) is seen more 
clearly. In the cerebellum (f), some neuronal axons and the Purkinje cells are positively stained. (m, molecular 




facilities or that the other isozymes are sufficient to compensate the lacking CA III. Another recent quantitative 
study on bioenergetics of the Car3оͬо mouse showed that these knockout mice, indeed, had significant defects 
in muscle function (Liu ym. 2007). It was concluded that the lack of CA III enzyme impairs mitochondrial ATP 
synthesis in the gastrocnemius muscle. CA III has also been implicated in fatty acid metabolism. It has been 
shown that the rat white adipose tissue has CA III concentration as high as 24% of the total cytosolic protein 
(Alver ym. 2004, Stanton ym. 1991). Adipocyte CA III expression has been observed to be lower in genetically or 
experimentally induced obese mice than in corresponding lean controls (Stanton ym. 1991). There has also 
been evidence that leptin and insulin somehow modulate CA III expression in rat adipose tissue, with leptin 
decreasing and insulin increasing its expression (Alver ym. 2004). This suggests that the decrease in CA III 
expression observed in obesity may be related to hyperleptinemia. It is supposed that CA III provides 
bicarbonate ion to convert acetyl-CoA into malonyl-CoA, necessary in lipogenesis. Since leptin inhibits fatty acid 
synthesis, it has been suggested that it might be due to leptin’s effect on CA III expression (Alver ym. 2004). 
 
According to previous studies CA III plays a role as an oxyradical scavenger of reactive oxygen species and 
protects cells from oxidative damage in both the liver and skeletal muscle (Raisanen ym. 1999, Zimmerman ym. 
2004). S-glutathiolation of two cysteine residues, Cys181 and Cys186, occurs rapidly on the surface of the CA III 
protein in hepatocytes under oxidative stress (Mallis ym. 2000). In the absence of glutathione, oxidants such as 
hydrogen peroxide, peroxyradicals, or hypochlorous acid were shown to produce irreversibly oxidized forms of 
these cysteine residues, primarily cysteine sulfinic acid or cysteic acid (Mallis ym. 2002). When GSH was 
present, the S-glutathionylation of cysteine residues of CA III occurred without any damage to the protein. 
Thus, CA III presumably participates in protection of proteins and cellular systems from irreversible oxidative 
processes. 
 
Recently, CAs have been demonstrated to be involved in tumor progression (Parkkila 2008). Acidic pH in 
extracellular environment of cancer cells contributes to an aggressive phenotype, which facilitates invasion and 
metastasis of tumor cells into new target organs. The expression of CA III in human hepatocellular carcinoma 
(HCC) has been studied by Kuo et al. (Kuo ym. 2003) who discovered that CA I, CA II and CA III protein 
expression levels are reduced in human HCC cells compared to the adjoining normal tissues. Dai et al. (Dai ym. 
2008) found that the overexpression of CA III results in increased acidity of both extracellular and intracellular 
environment. They also showed that lowered pH may activate the focal adhesion kinase (FAK) signaling 
pathway, which in turn plays an important role in cell spreading, migration, and survival. They hypothesized 
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that CA III is re-expressed in later stages of metastatic progression of HCC, and it might have an important 
influence in the development of metastasis in liver cancer. 
 
Table 1 Distribution of CA III in different mouse tissues. 
Organ      WB     IHC 
 
Stomach    -    +/- 
Duodenum    -    - 
Jejunum    -    - 
Ileum      +    - 
Colon     +    - 
Liver      ++    ++ 
Pancreas    -    ++ (only in D-cells) 
Spleen     -    - 
Kidney     +    +/- 
Submandibular gland   +    + 
Lung     +    - 
Skeletal muscle    +    ++ 
Heart      +    + 
Cerebrum    -    + 
Cerebellum    +    + 
Testis      +    +/- 
Scores in western blotting (WB) and immunohistochemistry (IHC): -, no reaction; +/-, very weak reaction; +, 
weak or moderate reaction; ++, strong reaction. 
 
 
CA III has been linked among other CAs, such as CA II, to autoimmune diseases. A recent study showed the 
presence of specific autoantibodies directed to CA III in the sera of rheumatoid arthritis (RA) patients (Robert-
Pachot ym. 2007). It was also discovered that CA III was overexpressed in the synovial membrane of RA 
patients but it was not observed in non-RA patients. The results led to a conclusion that CA III expression might 
result from a physiological response aimed at protecting cells from oxidative damage, and anti-CA III antibodies 
reduce the protective effect of CA III. However, further investigations are required to confirm the role of CA III 
in the pathophysiology of RA. Du et al. (Du ym. 2009) have also shown that the amount of CA III is diminished in 
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the skeletal muscle of myasthenia gravis patients. Thus, CA III insufficiency or antibody response against CA III 





The activation of CA III has been investigated only in few studies, and in fact, the first activation study of human 
CA III was published in 2008 by Supuran’s group (Vullo ym. 2008) who investigated the activation of human CA 
III and CA IV with a series of natural and non-natural amino acids and aromatic/heterocyclic amines. The same 
group had earlier reported the activation profiles of other mammalian catalytically active isoforms (Nishimori 
ym. 2007b, Pastorekova ym. 2008, Temperini ym. 2005, Temperini ym. 2006, Temperini ym. 2007, Vullo ym. 
2007a, Vullo ym. 2007b). The results concluded that the activation profile of human CA III was distinct from all 
other CA isoforms investigated so far. Only one amino acid was a good activator of human CA III while all the 
other effective derivatives were heterocyclic amines. Human CA III was effectively activated by D-His, 
serotonin, pyridyl-alkylamines, and aminoethyl-piperazine and morpholine, with their activation constants 
varying between 91 nM-1.12 µM. Notably, while the human CA III was very significantly activated by D-His, the 
enantiomeric form L-His was a much weaker activator. Similar effect was also observed with the other 
compounds and their enantiomers, also among the other CA isoforms. X-ray crystal data of the complexes of 
human CA I and II with L- and D-His has shown that both the stereoisomerism of the amino acid activator and 
the CA isoform define the binding site and orientation. Therefore, precise steric and electric properties are 
needed in the molecules of CA activators, in order to assure the formation of enzyme-activator complex. It was 
also observed that small modifications in the scaffold of some activators, for example adding a substituent in 
the phenyl moiety of L-Phe such as the phenolic moieties of L-DOPA lead to important changes in the CA 
activator properties. It is estimated that CA activators do not influence the binding of CO2 to the active site, but 
they interfere in the transfer of protons from the active site to the environment. This is described as the rate-
limiting step of the catalysis. It is supposed that the different activation profile of CA III isoform by amino acids 
and amines may be due to the different amino acid residues present in the active site. Those include Lys 
residue in position 64 and Leu residue in position 198, as discussed earlier in this article. (Vullo ym. 2008) 
 
There are two well-known classes of CA inhibitors: inorganic anions and sulfonamides/sulfamates (Supuran ja 
Scozzafava 2007). The inhibitors of the sulfonamide type, which constitute the principal type of classical CA 
inhibitors, bind to the catalytically critical Zn(II) ion of the enzyme active site. The organic part of the inhibitor 
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also participates in several hydrogen bonds with the hydrophilic and hydrophobic residues of the enzyme 
active site. For anionic inhibitors such as thiocyanate, nitrite, bisulfate etc. the interactions between inhibitor 
and enzyme are much simpler. CA III has been reported to be quite insensitive to sulfonamide inhibitors, which 
do not have enough space to bind in the vicinity of the Zn(II) ion, due to the presence of the bulky residue, 
Phe198 (Biswas ym. 2011). Only the very small sulfonamide, trifluoromethanesulfonamide, acts as a potent CA 
III inhibitor, with an inhibition constant of 0.9 µM (Supuran ja Scozzafava 2007). Clinically used compounds 
such as acetazolamide, methazolamide, topiramate, zonisamide and celecoxib are less effective CA III inhibitors 
(Nishimori ym. 2007a). CA III possesses a completely different inhibition profile with anions such as stannate, 
selenate, tellurate, persulfate, selenocyanate and trithiocarbonate when compared to the CA isoforms I, II, VII 
and XIII (Innocenti ym. 2009). These inorganic anions are somewhat less investigated. Trithiocarbonate 
inhibited human CA III efficiently, with an inhibition constant of 9.9 µM. Other investigated anionic inhibitors 
inhibit CA III with inhibition constants in the millimolar range. In another inhibition study with more common 
anions it was observed that fluoride, nitrate, nitrite, phenylboronic acid, and phenylarsonic acid were weak CA 
III inhibitors, whereas carbonate, cyanide, thiocyanate, azide and hydrogen sulfide were significantly more 
effective (Nishimori ym. 2009). It is important to understand the physiological functions of mammalian CA 
isozymes as well as the catalytic and inhibition mechanisms of these enzymes. This has resulted in the design of 
potent inhibitors, some of which possess important clinical applications (Supuran ym. 2004). Some inhibitors of 
CA isozymes are already widely used as antiglaucoma drugs, diuretics, antiepileptics, in the management of 
gastric and duodenal ulcers or osteoporosis among others (Supuran ja Scozzafava 2007). Today, extensive 
research is devoted in the drug design of anticancer agents and antiobesity drugs and CAs are clearly 





CA III has long been a neglected isozyme among the alpha-CA enzyme family because of its low catalytic 
activity. Recent studies have indicated, however, that CA III is involved in important physiological processes or 
phenomena, such as oxidative stress response, obesity, mitochondrial ATP synthesis, autoimmunity and 
carcinogenesis. Therefore, activation or inhibition of this enzyme by various compounds may offer a novel 
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